Casgevy

exagamglogene autotemcel

Approval

ApplicationBLA 125787
Approval dateDec 8, 2023
Approval year2023
SponsorVertex Pharmaceuticals Incorporated

FDA-approved use

STN 125787 - Treatment of sickle cell disease (SCD) and the treatment of transfusion dependent β-thalassemia (TDT) in patients 12 years of age and older

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Casgevy: